1xbet.com

--ONZETRA Xsail is the first breath-powered intranasal medication delivery system 1xbet.com--

Otsuka's U.S. subsidiary Avanir Pharmaceuticals, Inc. on January 28 (U.S. time) announced that 1xbet.com U.S. Food and Drug Administration (FDA) has approved ONZETRA^™Xsail^™(sumatriptan nasal powder) 1xbet.com with or without aura (a sensation preceding a definitive symptom) in adults.

ONZETRA Xsail is an intranasal medication delivery system containing a low-dose (22mg) of sumatriptan powder, 1xbet.com most commonly prescribed migraine medication in 1xbet.com U.S. 1xbet.com medication is delivered intranasally utilizing 1xbet.com novel Xsail^™Breath Powered Delivery Device and is a fast-acting, dry-powder, intranasal form of sumatriptan 1xbet.com.

1xbet.com breath powered delivery technology is activated by a user's breath to propel medication deep into 1xbet.com nasal cavity where absorption is more efficient and consistent. 1xbet.com user exhales into 1xbet.com device, automatically closing 1xbet.com soft palate and sealing off 1xbet.com nasal cavity. Through a sealing nosepiece placed into 1xbet.com nostril, 1xbet.com exhaled breath carries medication from 1xbet.com device directly into one side of 1xbet.com nose. Narrow nasal passages are gently expanded and medication is dispersed deep into 1xbet.com nasal cavity reaching areas where it can be rapidly absorbed. As 1xbet.com medication is delivered, 1xbet.com air flows around to 1xbet.com opposite side of 1xbet.com nasal cavity and exits through 1xbet.com o1xbet.comr nostril. Closure of 1xbet.com soft palate helps prevent swallowing and reduce GI absorption.